Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06010329 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Teligene US.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 9
- Study locations
NCT06010329 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Teligene US. The registered enrollment target is 66 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT06010329, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Teligene US.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 9
- Study locations
Study Summary
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Conditions Studied
Interventions
- DRUG Sutetinib Maleate Capsule
Study Locations (9)
California
- Oncology Physicians Network Healthcare - Glendale
- University of California San Diego Moores Cancer Center - La Jolla
New York
- Northwell Health - New Hyde Park
- Perlmutter Cancer Center - 34th Street - New York
Florida
- Moffitt Cancer Center - Tampa
Georgia
- University Cancer & Blood Center (UCBC) - Athens - Athens
Iowa
- Mission Cancer + Blood - Mission Cancer Foundation - Des Moines
Kentucky
- Norton Cancer Institute - Downtown - Louisville
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-12-27 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06010329
The ClinicalTrials.gov registry entry for NCT06010329 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Teligene US, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sutetinib Maleate Capsule is the first listed.
NCT06010329 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06010329 about?
NCT06010329 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC". The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
What is the current status of trial NCT06010329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2023-12-27. Estimated completion is 2026-04.
What conditions does trial NCT06010329 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06010329?
The interventions under investigation include: Sutetinib Maleate Capsule (DRUG).
Who is sponsoring clinical trial NCT06010329?
This trial is sponsored by Teligene US, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06010329 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.